Programmed death ligand-1 over-expression correlates with malignancy and contributes to immune regulation in ovarian cancerChristian J. Maine, Sadaf Ghaem‐Maghami, Nor Haslinda Abd Aziz et al.|Cancer Immunology Immunotherapy|2013Cited by 126
Clinical Use of Programmed Cell Death-1 and Its Ligand Expression as Discriminatory and Predictive Markers in Ovarian CancerJayanta Chatterjee, Sadaf Ghaem‐Maghami, Wei Dai et al.|Clinical Cancer Research|2016Cited by 51
Autoimmunity-Associated LYP-W620 Does Not Impair Thymic Negative Selection of Autoreactive T CellsDennis J. Wu, Nunzio Bottini, Wenbo Zhou et al.|PLoS ONE|2014Cited by 23
Supplementary Figure S3 from Clinical Use of Programmed Cell Death-1 and Its Ligand Expression as Discriminatory and Predictive Markers in Ovarian CancerJayanta Chatterjee, Sadaf Ghaem‐Maghami, Wei Dai et al.|Unknown|2023Cited by 0
Supplementary Table S2 from Clinical Use of Programmed Cell Death-1 and Its Ligand Expression as Discriminatory and Predictive Markers in Ovarian CancerJayanta Chatterjee, Sadaf Ghaem‐Maghami, Wei Dai et al.|Unknown|2023Cited by 0